Houston, United States
Plus Therapeutics, Inc., known for its slogan "Power and precision in cancer radiotherapeutics," stands as a noteworthy player in the pharmaceutical industry. Founded in 2019, this U.S.-based clinical-stage company is focused on developing cutting-edge radiotherapeutics targeted at rare and challenging cancer types affecting both adults and children. Their lead candidate, REYOBIQ™, is currently being tested in the multi-center ReSPECT clinical trials, targeting conditions such as recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.
Despite the absence of a headquarters location, Plus Therapeutics remains active in its growth strategy with a recent $15.00M Post IPO Equity investment secured as of January 1, 2026. As they continue to forge their path in achieving breakthrough therapeutic solutions, the company's strategic emphasis on rare cancers could present considerable investment potential in a specialized market segment.
